PMID- 12357369
OWN - NLM
STAT- MEDLINE
DCOM- 20021024
LR  - 20220316
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 16
IP  - 10
DP  - 2002 Oct
TI  - Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma 
      cells.
PG  - 2142-7
AB  - Interleukin 6 (IL-6) is known to play an important role in the biology of the 
      malignant plasma cells in multiple myeloma. In an effort to better understand 
      IL-6 stimulated myeloma cell growth, we have performed gene expression profiling 
      to identify IL-6 early response genes. Using the KAS-6/1 IL-6-dependent human 
      myeloma cell line, IL-6 stimulation dramatically induced expression of monocyte 
      chemoattractant protein-1 (MCP-1) mRNA. To verify this result, we used reverse 
      transcriptase PCR and RNAse protection assays and demonstrated using both assays 
      that MCP-1 is indeed an IL-6 responsive gene in a variety of IL-6-responsive 
      myeloma cell lines. Moreover, we also demonstrated IL-6 stimulated MCP-1 
      secretion by the myeloma cell lines as well as by fresh patient tumor cells. 
      Lastly, we present evidence that fresh patient tumor cells express mRNA for the 
      MCP-1 receptor, CCR2, as do myeloma cell lines along with a second MCP-1 
      receptor, CCR11. Although MM cell chemotaxis in response to MCP-1 was only 
      minimal, we were able to demonstrate that MCP-1 stimulated activation of MAPK. 
      Because of the important role that this chemokine plays in both angiogenesis and 
      bone homeostasis, and the ability of MCP-1 to activate myeloma cells, these 
      results suggest a new mechanism by which IL-6 may contribute to disease 
      pathogenesis.
FAU - Arendt, B K
AU  - Arendt BK
AD  - Department of Immunology, Mayo Graduate and Medical Schools, Mayo 
      Clinic/Foundation, Rochester, MN 55905, USA.
FAU - Velazquez-Dones, A
AU  - Velazquez-Dones A
FAU - Tschumper, R C
AU  - Tschumper RC
FAU - Howell, K G
AU  - Howell KG
FAU - Ansell, S M
AU  - Ansell SM
FAU - Witzig, T E
AU  - Witzig TE
FAU - Jelinek, D F
AU  - Jelinek DF
LA  - eng
GR  - CA62228/CA/NCI NIH HHS/United States
GR  - CA62242/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Chemokine CCL2)
RN  - 0 (DNA Primers)
RN  - 0 (DNA, Complementary)
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Base Sequence
MH  - Chemokine CCL2/*genetics
MH  - DNA Primers
MH  - DNA, Complementary
MH  - Enzyme Activation
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Humans
MH  - Interleukin-6/*physiology
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Multiple Myeloma/*metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA, Messenger/genetics
MH  - Tumor Cells, Cultured
EDAT- 2002/10/03 04:00
MHDA- 2002/10/31 04:00
CRDT- 2002/10/03 04:00
PHST- 2002/01/15 00:00 [received]
PHST- 2002/06/20 00:00 [accepted]
PHST- 2002/10/03 04:00 [pubmed]
PHST- 2002/10/31 04:00 [medline]
PHST- 2002/10/03 04:00 [entrez]
AID - 10.1038/sj.leu.2402714 [doi]
PST - ppublish
SO  - Leukemia. 2002 Oct;16(10):2142-7. doi: 10.1038/sj.leu.2402714.